It is argued that government policies must integrate psychologists into multidisciplinary neurological and geriatric teams, and that psychology training programs must be updated to prepare professionals for preventive roles.
Abstract
Recent advances in blood-based biomarkers have transformed the early diagnosis of Alzheimer’s disease (AD), enabling the identification of biological risk at preclinical and presymptomatic stages in a noninvasive and accessible manner. Despite this diagnostic progress, the expansion of psychological clinical services in dementia care has not kept pace, representing a critical gap in the current management of AD. This theoretical paper critically discusses the role of psychological clinical practice in the prevention and management of AD in light of these diagnostic advances, particularly from the perspective of the International Working Group (IWG), which defines AD as a clinical-biological entity and recommends that cognitively normal individuals with positive biomarkers be considered at risk rather than diagnosed. Based on this framework and on evidence from the 2024 Lancet Commission on dementia prevention, we propose a three-phase roadmap for the integration of psychological care into multidisciplinary AD management. Phase 1 encompasses universal prevention through psychoeducation, cognitive reserve promotion, and emotional education. Phase 2 targets at-risk individuals with elevated biomarker profiles, focusing on neuropsychological evaluation, risk disclosure support, and early cognitive intervention. Phase 3 addresses individuals with established AD through cognitive rehabilitation and caregiver support. We further argue that government policies must integrate psychologists into multidisciplinary neurological and geriatric teams, and that psychology training programs must be updated to prepare professionals for preventive roles. More research on standardized psychological protocols for pre-dementia contexts is urgently needed.
A review of recent advances in BBMs through the ATN-I framework explores how integrating BBMs with traditional cerebrospinal fluid and neuroimaging tests may support symptom-driven clinical triage, probability refinement, and early evaluation in selected individuals, improving clinical workflow efficiency and accessibi...
B. Xie, Wang Zhang, Yu Zhang et al.· Frontiers in Aging Neuroscie...· 0 citations
Modern criteria for Alzheimer’s disease (AD) suppose a clinical-biological nature of the disease. The increasingly widespread adoption of biomarker-based diagnostics for AD necessitates a clearer clinical profile of patients, particularly given a range of complex clinical, organizational and financial-economic issues...
Y. Shpilyukova, K. Nevzorova, E. Fedotova et al.· Russian neurological Journal· 0 citations
This chapter explores the pathophysiology of Alzheimer's Disease to identify peripheral molecular markers associated with these early events and facilitate the development of combinatorial therapies.
Sakshi Kumari, Amaan Rais, Mohd Suhail Ashar et al.· International review of neur...· 0 citations
A combination of biomarker-guided diagnostics with mechanism-based therapies might enable precision medicine approaches and improve clinical outcomes in AD.
Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia worldwide accounting for an estimated 60% to 80% of cases. Biomarkers play an integral role in AD randomized clinical trials (RCTs), providing objective measures of disease pathology, progression, and therapeutic effi...
Xiao-Lan Zhang, Michael F. Murphy, Henry J. Riordan et al.· Bioanalysis· 0 citations
A comparative review discusses recent original studies that have investigated the potential of AI-powered approaches in these three modalities for early detection of AD and discusses the challenges that need to be overcome for these techniques to translate into routine clinical practice.
H. Barber· American Journal for Young S...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.